Navigation Links
Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
Date:3/20/2012

uary 2017, is to develop tests to detect a variety of bacterial bioterrorism agents in the case of a terrorist attack. Principal investigator on the grant is Dr. David Alland of UMDNJ, and the work on select agents will be conducted in his laboratories.

"This is very similar to a previous NIAID-funded program conducted on tuberculosis, which supported development of six-color fluorescent detection and reagents-on-board," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "We considered that program to be a win-win because some of our tests, in addition to the MTB/RIF test, now employ six-color detection technology. We expect to see similar benefits — both direct and indirect — as a function of this new program, and expect to be able to fully leverage our capabilities in the areas of nested amplification and multiplex PCR pursuant to the next generation of GeneXpert products."

About the GeneXpert® System Molecular Diagnostic PlatformThe GeneXpert System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect, and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands found in clinical environments.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedica
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
3. Cepheid Welcomes Senior Vice President of Human Resources
4. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
5. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
6. Cepheid to Webcast Upcoming Financial Presentations
7. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
8. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
9. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
10. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
11. Cepheid Reports 2009 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. ... Worms, Germany has received good manufacturing practice (GMP) ... International Pharmaceutical Excipient Council (IPEC) Foundation. ... SYLOID® FP brand of pharmaceutical grade excipient silica ... Curtis Bay, Maryland (USA) and Sorocaba, Brazil locations. ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
... Feb. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences ... that on February 2, 2009 it received a letter ... the Company that the Panel has determined to grant ... Capital Market. The Panel granted the Company through ...
... CRY ), a biomaterials, medical device and tissue ... end financial results will be released on Thursday, February 19, ... live webcast at 10:00 a.m. Eastern Time, February 19, 2009, ... session hosted by Steven G. Anderson, president and CEO of ...
... first kidney-targeted antisense drug for type 2 diabetes enters ... (Nasdaq: ISIS ) announced today it has ... drug that inhibits the production of sodium dependent glucose ... transporter responsible for glucose re-absorption in the kidney. ...
Cached Biology Technology:Nasdaq Panel Grants Advanced Life Sciences Request for Continued Listing on Nasdaq Stock Market 2CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 2Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 3Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug 4
(Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... promising new class of drug designed to target the ... system, some of the HCV strains being treated exhibited ... team of Florida State University biologists, chemists and biomedical ... identify the drug-resistant HCV strains and the molecular-level mechanisms ...
... powerful new ability to engineer the flavor and aroma of ... publishing the most comprehensive deciphering of the beer,s "proteome" ever ... that make beer "beer") appears in ACS, monthly Journal ... say they were inspired to do the research by a ...
... has "significant" potential for preventing cardiomyopathy, a form of heart ... with diabetes, scientists have concluded in a new study. Their ... high risk for diabetic cardiomyopathy, appears in ACS, bi-weekly ... and colleagues note that people with diabetes have at least ...
Cached Biology News:Hepatitis C virus faces new weapon from Florida State scientists 2Hepatitis C virus faces new weapon from Florida State scientists 3
...
Request Info...
Human RUNX2/CBFA1 MAb (Clone 232902)...
... Streptavidin-Horseradish Peroxidase Conjugate, ... to reporter enzyme molecules ... and in situ hybridization ... Blotting & Labeling & ...
Biology Products: